<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04789837</url>
  </required_header>
  <id_info>
    <org_study_id>15/2021RHU</org_study_id>
    <nct_id>NCT04789837</nct_id>
  </id_info>
  <brief_title>The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis</brief_title>
  <official_title>The Phosphodiesterase 3 Inhibitor Cilostazol as an Adjunct to Conventional Therapy in Patients With Osteoarthritis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadat City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadat City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cilostazol is able to suppress the degradation of type II collagen in human chondrocytes&#xD;
      induced by IL-1b. Cilostazol add-on for celecoxib therapy has synergistic anti-arthritic&#xD;
      potential by inhibiting proinflammatory cytokine production in synovial fibroblasts through&#xD;
      the IL-10/SOCS3 pathways, consequently leading to the inhibition of synovial cell&#xD;
      proliferation and overcoming the perpetuation of synovial inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue scale assessment of pain</measure>
    <time_frame>week 12</time_frame>
    <description>the change of Visual Analogue Scale (VAS) pain score from baseline to posttreatment. Scores are recorded by making a handwritten mark on a 10-cm line that represents a continuum between &quot;no pain&quot; and &quot;worst pain.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC change</measure>
    <time_frame>week 12</time_frame>
    <description>the change of WOMAC Osteoarthritis Index from baseline to posttreatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the change of Short Form 36 Questionnaire (SF-36) score from baseline to posttreatment</measure>
    <time_frame>week 12</time_frame>
    <description>The SF-36 is a generic instrument to assess health-related quality of life. It consists of 36 questions and assesses 8 dimensions: physical functioning, role physical, pain index, general health, vitality, social functioning, role emotional, and mental health index. It also provides 2 summary measures of physical and mental components. The SF-36 score ranges from 0 to 100, with higher scores indicating better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug reaction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Clinical side effects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin 1 beta</measure>
    <time_frame>12 weeks</time_frame>
    <description>Interleukin 1 beta serum level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum level Tumor necrosis factor- alpha (TNF-α)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum level Tumor necrosis factor- alpha (TNF-α)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of IL-17</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum levels of IL-17</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of BDNF</measure>
    <time_frame>12 weeks</time_frame>
    <description>Serum levels of BDNF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum levels of IL-10</measure>
    <time_frame>12 WEEKS</time_frame>
    <description>Serum levels of IL-10</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet twice daily plus Celecoxib 200mg capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol 50 MG</intervention_name>
    <description>Cilostazol 50 mg twice daily plus Celecoxib 200mg capsule</description>
    <arm_group_label>Cilostazol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily plus Celecoxib 200mg capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Primary osteoarthritis Patients recruited were between 30 to 60 years of age, with&#xD;
             X-ray confirmed Kellgren-Lawrence grade13 II or III severity primary tibiofemoral OA,&#xD;
             according to the American College of Rheumatology criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those patients were excluded from the present study who:&#xD;
&#xD;
               -  were of age less than 30 years or more than 60 years&#xD;
&#xD;
               -  presented with active concomitant gastroduodenal disorders, hepatic and renal&#xD;
                  impairment within last 30 days prior to receiving the study drug&#xD;
&#xD;
               -  were diagnosed to have any inflammatory arthritis, gout or acute trauma of the&#xD;
                  knee, hip or spine; accompanying OA of the hip of sufficient severity to&#xD;
                  interfere with the functional assessment of the knee&#xD;
&#xD;
               -  had previous or ongoing treatment with oral SYSDOA (e.g., glucosamine sulphate,&#xD;
                  chondroitin sulphate, diacerein, piascledine), anti-depressants, tranquillisers,&#xD;
                  antacids or antibiotics; were having active cardiac lesion or hypertension, were&#xD;
                  pregnant females and those who were planning their pregnancy during the study&#xD;
&#xD;
               -  were having a known hypersensitivity to the used medications&#xD;
&#xD;
               -  have persistent diarrhoea or laxative use; severe gastrointestinal disorders,&#xD;
                  severe obesity, severe parenchymal organ disease, or anaemia (haemoglobin&lt; 10.0&#xD;
                  g/ dl or haematocrit &lt; 30%).&#xD;
&#xD;
               -  Patients who received oral, intramuscular, intraarticular or soft tissue&#xD;
                  injections of corticosteroids within last eight weeks before receiving the first&#xD;
                  dose of the study medication, or had undergone joint lavage and arthroscopic&#xD;
                  procedures in the previous 6 months, were also excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Pharmacy</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufia</state>
        <zip>13829</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mahmoud S Abdallah, PhD</last_name>
      <phone>01063340887</phone>
      <email>Mahmoud.samy@fop.usc.edu.eg</email>
    </contact>
    <contact_backup>
      <phone>+201063340887</phone>
      <email>Mahmoud.samy@fop.usc.edu.eg</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 6, 2021</study_first_submitted>
  <study_first_submitted_qc>March 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sadat City University</investigator_affiliation>
    <investigator_full_name>Mahmoud Samy Abdallah</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

